Rofecoxib (IPA: ) is a nonsteroidal anti-inflammatory drug (NSAID) that was used in the treatment of osteoarthritis, acute pain conditions, and dysmenorrhoea. Formerly marketed by Merck & Co. under the trade names Vioxx, Ceoxx and Ceeoxx, it was voluntarily withdrawn from the market in 2004 because of concerns about increased risk of heart attack and stroke.
Rofecoxib was one of the most widely used drugs ever to be withdrawn from the market. Worldwide, over 80 million people were prescribed rofecoxib at some time. In the year before withdrawal, Merck had a sales revenue of US$2.5 billion from Vioxx.
Rofecoxib was available on prescription as tablets and as an oral suspension.
More on
[ Rofecoxib ]
Analgesics and Anti Inflammatories :: Drugs and Medications
Rofecoxib - Twitter Search[伿¥] è²©å£²åæ¢ã®4å¹´ãåã«Merck社Vioxxã®å¿è¡ç®¡ãªã¹ã¯ã¯ææ¡ããã: ãã©ã»ã対ç
§ç¡ä½çºå試é¨ã®ã¡ã¿è§£æã®çµæãMerckï¼ã¡ã«ã¯ï¼ç¤¾ãVioxxï¼ãã¤ãªãã¯ã¹ï¼rofecoxibãããã§ã³ãã·ãï¼è²©å£²åæ¢ãçº.. http://bit.ly/4Pa6sfharashooter_bot (ãã©ã·ã§newsbot) Thu, 26 Nov 2009 00:21:31 -0000
[企業] 販売停止の4年も前にMerck社Vioxxの心血管リスクは把握しえた: プラセボ対照無作為化試験のメタ解析の結果、Merck(メルク)社がVioxx(バイオックス;rofecoxib、ロフェコキシブ)販売停止を発.. http://bit.ly/4Pa6sf
Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safe.. http://bit.ly/7FuYbboatp (OA Tracking Project) Wed, 25 Nov 2009 18:44:14 -0000
Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safe.. http://bit.ly/7FuYbb
Adverse Heart Effects of Rofecoxib May Have Been Identified Years Earlier http://bit.ly/8POg5WNurseDianeW (Diane Wachowski) Tue, 24 Nov 2009 20:48:12 -0000
Adverse Heart Effects of Rofecoxib May Have Been Identified Years Earlier http://bit.ly/8POg5W
Post: "Rofecoxib's adverse heart effects may have been identified years earlier" http://tinyurl.com/yay4ar7DCNewsOverviews (DC News) Tue, 24 Nov 2009 15:51:51 -0000
Post: "Rofecoxib's adverse heart effects may have been identified years earlier" http://tinyurl.com/yay4ar7
Unpublished Research Signaled Rofecoxib CV Risk as Early as 2001, Study Alleges: http://egmn.idsk.com/stories_global/46_ds_9471348.jspCardioNews (Cardiology News) Tue, 24 Nov 2009 15:12:49 -0000
Unpublished Research Signaled Rofecoxib CV Risk as Early as 2001, Study Alleges: http://egmn.idsk.com/stories_global/46_ds_9471348.jsp
Unpublished Research Signaled Rofecoxib CV Risk as Early as 2001, Study Alleges: http://egmn.idsk.com/stories_global/46_ds_9471348.jspClinEndoNews (Clinical Endocrinolo) Tue, 24 Nov 2009 15:12:49 -0000
Unpublished Research Signaled Rofecoxib CV Risk as Early as 2001, Study Alleges: http://egmn.idsk.com/stories_global/46_ds_9471348.jsp
Subscribe to Rofecoxib RSS feed 
Dolib - Product description, prescribing information, clinical studies, abstracts and a discussion board for the Cox-2 in inhibitor rofecoxib.
DrugDigest: Rofecoxib ( Vioxx ) - Information on dosage, usage, side effects, interactions, and drug comparisons, including generics when available.
Spine-Health - Information on Vioxx (Cox 2 inhibitors) and osteoarthritis and back pain.
Meta Description: [ COX-2 inhibitors - Celebrex, a new type of medication for back pain, by Spine-Health. ]
Vioxx.com - Find information on the treatment of osteoarthritis symptoms and pain. For patients and professionals.